Cited by 278Schizophrenia research and treatmentNeuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients

Pilowsky, L S, Bressan, R A, Stone, J M, Erlandsson, K, Mulligan, R S, Krystal, J H, Ell, P J·2006·Molecular Psychiatry

DOI 10.1038/sj.mp.4001751

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1038/sj.mp.4001751

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Statistical parametric maps in functional imaging: A general linear approach
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688
Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia
Coyle, J. T., Tsai, G. E., & GOFF, D. C. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.020 · Cited by 443
Usefulness of a three-dimensional stereotaxic ROI template on anatomically standardised 99mTc-ECD SPET
Takeuchi, R., Yonekura, Y., Matsuda, H., & Konishi, J. (2002) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-001-0715-z · Cited by 134
Impact of Schizophrenia and Chronic Antipsychotic Treatment on [123I]CNS-1261 Binding to N-Methyl-D-Aspartate Receptors In Vivo
Bressan, R. A., Erlandsson, K., Stone, J. M., Mulligan, R. S., Krystal, J. H., Ell, P. J., & Pilowsky, L. S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.016 · Cited by 57
Self-citation
Kinetic modelling of [123I]CNS 1261—a potential SPET tracer for the NMDA receptor
Erlandsson, K., Bressan, R. A., Mulligan, R. S., Gunn, R. N., Cunningham, V. J., Owens, J., Wyper, D. J., Ell, P. J., & Pilowsky, L. S. (2003) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(02)00450-x · Cited by 40
Self-citation
Untitled work
Lurito (2000) · doi:10.1002/1097-0193(200007)10:3

Flagged first, then by citations

Show all 6 references

Research works printed but not linked: 1

Stone J, Erlandsson K, Arstad E, Bressan RA, Teneggi V, Ell PJ et al. Schizophrenia Bull 2005; 31 (2): 446.

Sorted by citations

Items 101–200 of 278

Microarray-Based Genomic DNA Profiling Technologies in Clinical Molecular Diagnostics
Shen, Y., & Wu, B.-L. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.112821 · Cited by 55
Development of PET and SPECT Probes for Glutamate Receptors
Fuchigami, T., Nakayama, M., & Yoshida, S. (2015) · The Scientific World JOURNAL · doi:10.1155/2015/716514 · Cited by 53
New Drug Treatments for Schizophrenia: A Review of Approaches to Target Circuit Dysfunction
Howes, O. D., Dawkins, E., Lobo, M. C., Kaar, S. J., & Beck, K. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.05.014 · Cited by 53
Expression of the Hippocampal NMDA Receptor GluN1 Subunit and Its Splicing Isoforms in Schizophrenia: Postmortem Study
Vrajová, M., Šťastný, F., Horáček, J., Lochman, J., Šerý, O., Peková, Š., Klaschka, J., & Höschl, C. (2010) · Neurochemical Research · doi:10.1007/s11064-010-0145-z · Cited by 54
Neurofilament light interaction with GluN1 modulates neurotransmission and schizophrenia-associated behaviors
Yuan, A., Veeranna, Sershen, H. W., Basavarajappa, B. S., Smiley, J. F., Hashim, A., Bleiwas, C., Berg, M. J., Guifoyle, D. N., Subbanna, S., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0194-7 · Cited by 54
Proton Magnetic Resonance Spectroscopy in 22q11 Deletion Syndrome
Alves, F. D. S., Boot, E., Schmitz, N., Nederveen, A. J., Vorstman, J. A. S., Lavini, C., Pouwels, P. J. W., de Haan, L., LINSZEN, D. H., & van Amelsvoort, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021685 · Cited by 50
Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis
Wiescholleck, V., & Manahan‐Vaughan, D. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.01.001 · Cited by 54
Disturbed synaptic connectivity in schizophrenia: Convergence of genetic risk factors during neurodevelopment
Hayashi‐Takagi, A., & Sawa, A. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.04.007 · Cited by 50
Role of N-Methyl D-aspartate receptors in action-based predictive coding deficits in schizophrenia
Kort, N. S., Ford, J. M., Roach, B. J., Gunduz-Bruce, H., Krystal, J. H., Jaeger, J., Reinhart, R. M. G., & Mathalon, D. H. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.06.019 · Cited by 48
Self-citation
NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia
Ramsey, A. J. (2009) · Progress in brain research · doi:10.1016/s0079-6123(09)17906-2 · Cited by 50
The Glutamate Hypothesis of Schizophrenia: Neuroimaging and Drug Development
Egerton, A., & Stone, J. M. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800784961 · Cited by 51
Self-citation
A Brief Assessment of Intelligence Decline in Schizophrenia As Represented by the Difference between Current and Premorbid Intellectual Quotient
Ohi, K., Sumiyoshi, C., Fujino, H., Yasuda, Y., Yamamori, H., Fujimoto, M., Sumiyoshi, T., & Hashimoto, R. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00293 · Cited by 48
Review: The biological basis of antipsychotic response in schizophrenia
Stone, J. M., Raffin, M., Morrison, P., & McGuire, P. K. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109106959 · Cited by 49
Self-citation
Switching schizophrenia patients from typical neuroleptics to aripiprazole: Effects on working memory dependent functional activation
Schlagenhauf, F., Dinges, M., Beck, A., Wüstenberg, T., Friedel, E., Dembler, T., Sarkar, R., Wrase, J., Gallinat, J., Juckel, G., et al. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.01.022 · Cited by 49
NMDA Receptor Phosphorylation at a Site Affected in Schizophrenia Controls Synaptic and Behavioral Plasticity
Li, B., Devidze, N., Barengolts, D., Prostak, N., Sphicas, E., Apicella, A. J., Malinow, R., & Emamian, E. S. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.2109-09.2009 · Cited by 48
Role of glutamate in schizophrenia: integrating excitatory avenues of research
Sodhi, M., Wood, K. H., & Meador‐Woodruff, J. H. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.9.1389 · Cited by 49
Molecular imaging of schizophrenia: Neurochemical findings in a heterogeneous and evolving disorder
Cumming, P. D., Abi‐Dargham, A., & Gründer, G. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113004 · Cited by 53
Impaired GABAergic neurotransmission in schizophrenia underlies impairments in cortical gamma band oscillations
McNally, J. M., McCarley, R. W., & Brown, R. E. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-012-0346-z · Cited by 47
The Role of Striatal-Enriched Protein Tyrosine Phosphatase (STEP) in Cognition
Fitzpatrick, C. J., & Lombroso, P. J. (2011) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2011.00047 · Cited by 48
Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis
Chana, G., Bousman, C., Money, T., Gibbons, A. S., Gillett, P., Dean, B., & Everall, I. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00095 · Cited by 44
Pregnenolone sulfate normalizes schizophrenia-like behaviors in dopamine transporter knockout mice through the AKT/GSK3β pathway
Wong, P., Sze, Y., Chang, C. C. R., Lee, J., & Zhang, X. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.21 · Cited by 45
Specific Roles of NMDA Receptor Subunits in Mental Disorders
Yamamoto, H., Hagino, Y., Kasai, S., & Ikeda, K. (2015) · Current Molecular Medicine · doi:10.2174/1566524015666150330142807 · Cited by 48
Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis
Shakory, S., Watts, J. J., Hafizi, S., Silva, T. M. S., Khan, S. M., Michael Kiang, A., Bagby, R. M., Chavez, S., & Mizrahi, R. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0163-0 · Cited by 44
The interhemispheric miscommunication theory of auditory verbal hallucinations in schizophrenia
Steinmann, S., Leicht, G., & Mulert, C. (2019) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2019.02.002 · Cited by 44
Effects of antipsychotic drugs on neurites relevant to schizophrenia treatment
Huang, X., & Song, X. (2018) · Medicinal Research Reviews · doi:10.1002/med.21512 · Cited by 45
NR2C in the Thalamic Reticular Nucleus; Effects of the NR2C Knockout
Zhang, Y., Buonanno, A., Vertes, R. P., Hoover, W. B., & Lisman, J. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041908 · Cited by 41
Group II metabotropic glutamate receptors modify N-methyl-D-aspartate receptors via Src kinase
Trepanier, C. H., Lei, G., Xie, Y., & MacDonald, J. F. (2013) · Scientific Reports · doi:10.1038/srep00926 · Cited by 39
mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia
Brambilla, C. R., Veselinović, T., Rajkumar, R., Mauler, J., Orth, L., Ruch, A., Ramkiran, S., Heekeren, K., Kawohl, W., Wyss, C., et al. (2020) · Human Brain Mapping · doi:10.1002/hbm.24976 · Cited by 37
Is Memantine Effective as an NMDA Receptor Antagonist in Adjunctive Therapy for Schizophrenia?
Kikuchi, T. (2020) · Biomolecules · doi:10.3390/biom10081134 · Cited by 37
Metabotropic Glutamate Receptors for New Treatments in Schizophrenia
Herman, E. J., Bubser, M., Conn, P. J., & Jones, C. K. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_11 · Cited by 37
Glutamate and Psychosis Risk
Egerton, A., Fusar-Poli, P., & M. Stone, J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799316244 · Cited by 36
Self-citation
N-Methyl D-Aspartate Receptor Antagonist Kynurenic Acid Affects Human Cortical Development
Bagasrawala, I., Zečević, N., & Radonjić, N. V. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00435 · Cited by 39
Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development
Müller, N. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220802507852 · Cited by 35
Advancing a functional genomics for schizophrenia: Psychopathological and cognitive phenotypes in mutants with gene disruption
Kirby, B. P., Waddington, J. L., & O’Tuathaigh, C. M. P. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.09.010 · Cited by 36
Review of Major Social Determinants of Health in Schizophrenia-Spectrum Psychotic Disorders: III. Biology
Jeste, D. V., Malaspina, D., Bagot, K. S., Barch, D. M., Cole, S. W., Dickerson, F., Dilmore, A. H., Ford, C. L., Karcher, N. R., Luby, J. L., et al. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad031 · Cited by 38
Impaired working memory by repeated neonatal MK-801 treatment is ameliorated by galantamine in adult rats
Su, Y., Huang, R.-H., Wang, X., Li, J., & Si, T. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.01.007 · Cited by 33
Synapse pathology and translational applications for schizophrenia
Hayashi‐Takagi, A. (2016) · Neuroscience Research · doi:10.1016/j.neures.2016.09.001 · Cited by 32
Clozapine functions through the prefrontal cortex serotonin 1A receptor to heighten neuronal activityviacalmodulin kinase II–NMDA receptor interactions
Purkayastha, S., Ford, J. R., Kanjilal, B., Diallo, S., Inigo, J. D. R., Neuwirth, L. S., Idrissi, A. E., Ahmed, Z., Wieraszko, A., Azmitia, E. C., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07565.x · Cited by 32
Beyond Dopamine: Glutamate as a Target for Future Antipsychotics
Sendt, K.-V., Giaroli, G., & Tracy, D. K. (2012) · ISRN Pharmacology · doi:10.5402/2012/427267 · Cited by 34
Mutation screening of GRIN2B in schizophrenia and autism spectrum disorder in a Japanese population
Takasaki, Y., Koide, T., Wang, C., Kimura, H., Xing, J., Kushima, I., Ishizuka, K., Mori, D., Sekiguchi, M., Ikeda, M., et al. (2016) · Scientific Reports · doi:10.1038/srep33311 · Cited by 29
Genomic Imprinting and Human Psychology: Cognition, Behavior and Pathology
Goos, L. M., & Ragsdale, G. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-77576-0_6 · Cited by 30
Animal Models of Schizophrenia
Yanagi, M., Southcott, S. A., Lister, J. M., & Tamminga, C. A. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-394596-9.00012-3 · Cited by 32
Neurochemistry of schizophrenia: the contribution of neuroimaging postmortem pathology and neurochemistry in schizophrenia.
Dean, B. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612805289935 · Cited by 30
N-methyl-D-aspartate receptor hypofunction as a potential contributor to the progression and manifestation of many neurological disorders
Dong, B., Yang, Y., Han, D., & Wang, Y. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1174738 · Cited by 30
Assessment of auditory sensory processing in a neurodevelopmental animal model of schizophrenia—Gating of auditory-evoked potentials and prepulse inhibition
Broberg, B. V., Oranje, B., Glenthoj, B. Y., Fejgin, K., Plath, N., & Bastlund, J. F. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.04.026 · Cited by 27
Cognitive correlates of visual neural plasticity in schizophrenia
Jahshan, C. S., Wynn, J. K., Mathalon, D. H., & Green, M. F. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.03.016 · Cited by 27
Magnesium in schizophrenia
Ordak, M., Matras, J., Muszyńska, E., Nasierowski, T., & Bujalska‐Zadrożny, M. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.03.022 · Cited by 26
Neurochemical dysfunction in treated and nontreated schizophrenia – a retrospective analysis of in vivo imaging studies
Nikolaus, S., Hautzel, H., & Müller, H. (2014) · Reviews in the Neurosciences · doi:10.1515/revneuro-2013-0063 · Cited by 26
Neuregulin 1 Controls Glutamate Uptake by Up-regulating Excitatory Amino Acid Carrier 1 (EAAC1)
Yu, H.-N., Park, W.-K., Nam, K., Song, D., Kim, H., Baik, T., & Woo, R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.591867 · Cited by 26
The effect of a full agonist/antagonist of the D1 receptor on locomotor activity, sensorimotor gating and cognitive function in dizocilpine-treated rats
Bubeníková‐Valešová, V., Svoboda, J., Horáček, J., & Valeš, K. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009851 · Cited by 28
Long-term potentiation prevents ketamine-induced aberrant neurophysiological dynamics in the hippocampus-prefrontal cortex pathway in vivo
Lopes‐Aguiar, C., Ruggiero, R. N., Rossignoli, M. T., Esteves, I. D. M., Peixoto-Santos, J. E., Romcy-Pereira, R. N., & Leite, J. P. (2020) · Scientific Reports · doi:10.1038/s41598-020-63979-5 · Cited by 21
When the drugs don't work: the potential of glutamatergic antipsychotics in schizophrenia
Papanastasiou, E., Stone, J. M., & Shergill, S. S. (2013) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.112.110999 · Cited by 24
Self-citation
N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging study
Beck, K., Arumuham, A., Veronese, M., Santangelo, B., McGinnity, C., Dunn, J., McCutcheon, R., Kaar, S., Singh, N., Pillinger, T., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01540-2 · Cited by 20
Self-citation
Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and d-amphetamine models of schizophrenia
Profaci, C. P., Krolikowski, K. A., Olszewski, R. T., & Neale, J. H. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2200-0 · Cited by 23
Alterations in prefrontal glutamatergic and noradrenergic systems following MK-801 administration in rats prenatally exposed to methylazoxymethanol at gestational day 17
Léna, I., Chessel, A., Pen, G. L., Krebs, M., & Garcia, R. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0719-x · Cited by 23
Immunologische Aspekte bei schizophrenen Störungen
Müller, N., & Schwarz, M. (2006) · Der Nervenarzt · doi:10.1007/s00115-006-2108-9 · Cited by 22
Evaluation of state and trait biomarkers in healthy volunteers for the development of novel drug treatments in schizophrenia
Koychev, I., Barkus, E., Ettinger, U., Killcross, S., Roiser, J. P., Wilkinson, L., & Deakin, B. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111414450 · Cited by 24
Impaired Potentiation of Theta Oscillations During a Visual Cortical Plasticity Paradigm in Individuals With Schizophrenia
Hamilton, H., Roach, B. J., Çavuş, I., Teyler, T. J., Clapp, W. C., Ford, J. M., Tarakci, E., Krystal, J. H., & Mathalon, D. H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.590567 · Cited by 22
Self-citation
Retracted
Kynurenines, Gender and Neuroinflammation; Showcase Schizophrenia
de Bie, J., Lim, C. K., & Guillemin, G. J. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9641-5 · Cited by 21
A Neurophysiological Perspective on a Preventive Treatment against Schizophrenia Using Transcranial Electric Stimulation of the Corticothalamic Pathway
Pinault, D. (2017) · Brain Sciences · doi:10.3390/brainsci7040034 · Cited by 23
Genetic association analysis of N‐methyl‐ d ‐aspartate receptor subunit geneGRIN2Band clinical response to clozapine
Taylor, D. L., Tiwari, A. K., Lieberman, J. A., Potkin, S. G., Meltzer, H. Y., Knight, J., Remington, G. J., Müller, D. J., & Kennedy, J. L. (2016) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2519 · Cited by 20
Disrupted local beta band networks in schizophrenia revealed through graph analysis: A magnetoencephalography study
Tagawa, M., Takei, Y., Kato, Y., Suto, T., Hironaga, N., Ohki, T., Takahashi, Y., Fujihara, K., Sakurai, N., Ujita, K., et al. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13362 · Cited by 19
The Enduring Centrality of Dopamine in the Pathophysiology of Schizophrenia
Bonoldi, I., & Howes, O. D. (2013) · Advances in pharmacology · doi:10.1016/b978-0-12-411512-5.00010-5 · Cited by 19
Possible Effects of Synaptic Imbalances on Oligodendrocyte–Axonic Interactions in Schizophrenia: A Hypothetical Model
Mitterauer, B., & Kofler-Westergren, B. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00015 · Cited by 20
Current understanding on the role of nitric oxide and therapeutic potential of NO supplementation in schizophrenia
Oh, S. J., & Fan, X. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.05.050 · Cited by 19
Neurochemical Imaging in Schizophrenia
Urban, N., & Abi‐Dargham, A. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_37 · Cited by 18
Impaired functional connectivity of the hippocampus in translational murine models of NMDA-receptor antibody associated neuropsychiatric pathology
Kuchling, J., Jurek, B., Kents, M., Kreye, J., Geis, C., Wickel, J., Mueller, S. G., Koch, S., Boehm‐Sturm, P., Prüß, H., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02303-9 · Cited by 21
Contributions of Glutamate and GABA Systems to the Neurobiology and Treatment of Schizophrenia
Krystal, J. H., & Moghaddam, B. (2010) · Wiley eBooks · doi:10.1002/9781444327298.ch21 · Cited by 17
Self-citation
Schizophrenia-Like Behavioral Impairments in Mice with Suppressed Expression of Piccolo in the Medial Prefrontal Cortex
Nitta, A., Izuo, N., Hamatani, K., Inagaki, R., Kusui, Y., Fu, K., Asano, T., Torii, Y., Habuchi, C., Sekiguchi, H., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070607 · Cited by 15
Global quantitative analysis of phosphorylation underlying phencyclidine signaling and sensorimotor gating in the prefrontal cortex
McClatchy, D. B., Savas, J. N., Martínez‐Bartolomé, S., Park, S. K., Maher, P. A., Powell, S. B., & Yates, J. R. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.41 · Cited by 14
Adolescent stress leads to glutamatergic disturbance through dopaminergic abnormalities in the prefrontal cortex of genetically vulnerable mice
Matsumoto, Y., Niwa, M., Mouri, A., Noda, Y., Fukushima, T., Ozaki, N., & Nabeshima, T. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4704-8 · Cited by 15
Biological Psychiatry and Psychopharmacology
Fountoulakis, K. N., Nimatoudis, I., & Stahl, S. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-18323-3_13 · Cited by 17
Oxidative Stress-Mediated Neuroinflammation in the Pathophysiology of Schizophrenia
Trubalski, M., Markiewicz-Gospodarek, A., Żerebiec, M., Poleszak, J., Szczotka, M., Markiewicz, R., Łoza, B., & Szymańczyk, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211139 · Cited by 17
Genetically modified mice related to schizophrenia and other psychoses: Seeking phenotypic insights into the pathobiology and treatment of negative symptoms
O’Tuathaigh, C. M. P., Desbonnet, L., & Waddington, J. L. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.08.009 · Cited by 16
Interaction between effects of genes coding for dopamine and glutamate transmission on striatal and parahippocampal function
Pauli, A., Prata, D. P., Mechelli, A., Picchioni, M., Fu, C. H. Y., Chaddock, C. A., Kane, F., Kalidindi, S., McDonald, C., Kravariti, E., et al. (2012) · Human Brain Mapping · doi:10.1002/hbm.22061 · Cited by 14
Cerebral Metabolic Effects of Intravenous Glycine in Healthy Human Subjects
Neumeister, A., Carson, R. E., Henry, S. E., Planeta‐Wilson, B., Binneman, B., Maguire, R. P., Luckenbaugh, D. A., D’Souza, C., Krystal, J. H., & Frost, J. J. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000245558.14284.aa · Cited by 14
Self-citation
Controversial Effects of D-Amino Acid Oxidase Activator (DAOA)/G72 on D-Amino Acid Oxidase (DAO) Activity in Human Neuronal, Astrocyte and Kidney Cell Lines: The N-methyl D-aspartate (NMDA) Receptor Hypofunction Point of View
Jagannath, V., Brotzakis, Z. F., Parrinello, M., Walitza, S., & Grünblatt, E. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00342 · Cited by 13
Imaging as Tool to Investigate Psychoses and Antipsychotics
Booij, J., & van Amelsvoort, T. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_12 · Cited by 14
Molecular Genetic Models Related to Schizophrenia and Psychotic Illness: Heuristics and Challenges
O’Tuathaigh, C. M. P., Desbonnet, L., Moran, P. M., Kirby, B. P., & Waddington, J. L. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_111 · Cited by 13
Brain volume in chronic ketamine users — relationship to sub-threshold psychotic symptoms and relevance to schizophrenia
Chesters, R., Pepper, F., Morgan, C. J. A., Cooper, J. D., Howes, O. D., Vernon, A. C., & Stone, J. M. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05873-0 · Cited by 11
Self-citation
Effects of MK-801 treatment across several pre-clinical analyses including a novel assessment of brain metabolic function utilizing PET and CT fused imaging in live rats
Daya, R. P., Bhandari, J., Hui, P., Tian, Y., Farncombe, T. H., & Mishra, R. K. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.10.001 · Cited by 11
Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophrenia
Griffiths, K., Smart, S. E., Barker, G. J., Deakin, J. F. W., Lawrie, S. M., Lewis, S. W., Lythgoe, D. J., Pardiñas, A. F., Singh, K. D., Semple, S., et al. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.08.020 · Cited by 11
Dopamine Receptors and the Treatment of Schizophrenia
Ginovart, N., & Kapur, S. (2009) · The Receptors · doi:10.1007/978-1-60327-333-6_16 · Cited by 11
Is Forced Swimming Immobility a Good Endpoint for Modeling Negative Symptoms of Schizophrenia? - Study of Sub-Anesthetic Ketamine Repeated Administration Effects
Neves, G. A., Borsoï, M., Antonio, C. B., Pranke, M. A., Betti, A. H., & Rates, S. M. K. (2017) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201720160844 · Cited by 11
The predictive value of baseline NAA/Cr for treatment response of first-episode schizophrenia: A 1H MRS study
Liu, W., Yu, H., Jiang, B., Pan, B., Yu, S., Li, H., & Zheng, L. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.06.029 · Cited by 13
GluN2B protein deficits in the left, but not the right, hippocampus in schizophrenia
Geddes, A. E., Huang, X., & Newell, K. A. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0274-z · Cited by 11
How have developments in molecular imaging techniques furthered schizophrenia research?
Thompson, J. L., Urban, N., & Abi‐Dargham, A. (2009) · Imaging in Medicine · doi:10.2217/iim.09.22 · Cited by 9
Visual cortical plasticity and the risk for psychosis: An interim analysis of the North American Prodrome Longitudinal Study
Jacob, M., Roach, B. J., Hamilton, H., Carrión, R. E., Belger, A., Duncan, E., Johannesen, J., Keshavan, M. S., Loo, S. K., Niznikiewicz, M. A., et al. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.01.028 · Cited by 13
The Emerging Role of SPECT Functional Neuroimaging in Schizophrenia and Depression
Kalyoncu, A., & Gönül, A. S. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.716600 · Cited by 11
Glycolytic and Krebs cycle enzymes activity in rat prefrontal cortex, hippocampus, and striatum after single and repeated NMDA inhibition by MK-801
Kolář, D., Kletečková, L., Skálová, K., Brožka, H., Kalous, M., & Valeš, K. (2022) · NeuroToxicology · doi:10.1016/j.neuro.2022.02.005 · Cited by 9
Predicting protein–protein interactions in the post synaptic density
Bar-Shira, O., & Chechik, G. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2013.04.004 · Cited by 7
Susceptibility Genes for Schizophrenia: Mutant Models, Endophenotypes and Psychobiology
O’Tuathaigh, C. M. P., Desbonnet, L., Moran, P. M., & Waddington, J. L. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_194 · Cited by 8
Acquisition of nicotine self-administration in amphetamine and phencyclidine models of schizophrenia: A role for stress?
Fletcher, P., Li, Z., Coen, K., & Lê, A. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.02.028 · Cited by 8
NEUROTRANSMITTER AND BRAIN PARTS INVOLVED IN SCHIZOPHRENIA
Arya, A., Sindhwani, G., & Kadian, R. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11i6.24557 · Cited by 8
Relationship Between Replay-Associated Ripples and Hippocampal N-Methyl-D-Aspartate Receptors: Preliminary Evidence From a PET-MEG Study in Schizophrenia
Nour, M. M., Beck, K., Liu, Y., Arumuham, A., Veronese, M., Howes, O. D., & Dolan, R. J. (2022) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgac044 · Cited by 8
The association between N-methyl-d-aspartate receptor availability and glutamate levels: A multi-modal PET-MR brain imaging study in first-episode psychosis and healthy controls
Beck, K., Arumuham, A., Brugger, S., McCutcheon, R., Veronese, M., Santangelo, B., McGinnity, C., Dunn, J., Kaar, S., Singh, N., et al. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221099643 · Cited by 6
Self-citation
A critical role for NMDA receptors in parvalbumin interneurons for gamma induction and behavior
Carlén, M., Meletis, K., Siegle, J. H., Cardin, J. A., Futai, K., Vierling-Claassen, D., Rühlmann, C., Jones, S. R., Deisseroth, K. A., Sheng, M., et al. (2011) · PubMed Central · Cited by 7
Modeling Schizophrenia in Animals
Feifel, D., & Shilling, P. D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415894-8.00030-0 · Cited by 8
Cytokines, Immunity and Schizophrenia with Emphasis on Underlying Neurochemical Mechanisms
Müller, N., & Schwarz, M. (2008) · Springer eBooks · doi:10.1007/978-0-387-84851-8_15 · Cited by 7
Correction: Proton Magnetic Resonance Spectroscopy in 22q11 Deletion Syndrome
Alves, F. D. S., Boot, E., Schmitz, N., Nederveen, A. J., Vorstman, J. A. S., Lavini, C., Pouwels, P. J. W., de Haan, L., LINSZEN, D. H., & van Amelsvoort, T. (2011) · PLoS ONE · doi:10.1371/annotation/805ba3f5-0fd7-41f9-bc2c-31ebf507f05b · Cited by 7

Authors: Pilowsky, L. S., Bressan, R. A., Stone, J. M., Erlandsson, K., Mulligan, R. S., Krystal, J. H., & Ell, P. J.
Affiliations: King's College London (GB)
University College London (GB)
Yale University (US)
ORCID: Bressan, R A
Stone, J M
Erlandsson, K
Krystal, J H
Venue: Molecular Psychiatry
Publisher: Springer Science and Business Media LLC
Published: 2005-09-27
Volume: 11
Issue: 2
Pages: 118-119
ISSN: 1359-4184 (ISSN-L)
1476-5578
DOI: 10.1038/sj.mp.4001751
OpenAlex: W2066489132
Cited by: 278
References: 6
Citations by year: 2026: 1 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 11 · 2021: 9 · 2020: 11 · 2019: 8 · 2018: 7 · 2017: 14 · 2016: 20 · 2015: 19 · 2014: 16 · 2013: 21 · 2012: 17
FWCI: 6.65
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Molecular Psychiatry (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Research Portal (King's College London) (submittedVersion)
Funders: National Institutes of Health (5k05aa014906-03)
National Institute on Alcohol Abuse and Alcoholism (KO5 AA 014906-02)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: NMDA receptor, schizophrenia, medication-free patients, receptor availability, first-episode psychosis, ketamine, brain volume
MeSH terms: Analysis of Variance, Clozapine, Guanidines, Hippocampus, Humans, Functional Laterality, Reference Values, Schizophrenia, Tissue Distribution, Antipsychotic Agents, Tomography, Emission-Computed, Single-Photon, Case-Control Studies, Receptors, N-Methyl-D-Aspartate, Genetic Predisposition to Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks